RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 15 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 15

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  2. Study siteChina-Japan Friendship Hospital中日友好医院BeijingHospital page
  3. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  4. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  5. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  6. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  7. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  8. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  9. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  10. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  11. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  12. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  13. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  14. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  15. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT03936153, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed diffuse large B-cell lymphoma (DLBCL);

    Inclusion criterion 1

  3. Have received only two prior standard therapy lines for diffuse large B-cell lymphoma (DLBCL) including anti- cluster of differentiation antigen (anti-CD20) antibody and cytotoxic therapy;

    Inclusion criterion 2

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;

    Inclusion criterion 5

  5. Evidence of possible human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV) infection;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT03936153, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically confirmed diffuse large B-cell lymphoma (DLBCL);
  • Have received only two prior standard therapy lines for diffuse large B-cell lymphoma (DLBCL) including anti- cluster of differentiation antigen (anti-CD20) antibody and cytotoxic therapy;
  • Confirmed to be unresponsive to the last line of therapy, or have disease progression following the last line of therapy;
  • Have at least one radiologically measurable lymph node or extranodal lymphoid malignant lesion;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;
  • Meet various hematological, liver and renal function lab parameters.

Exclusion Criteria:

  • Have primary central nervous system (CNS) lymphoma or secondary central nervous system (CNS) infiltration, transformed lymphoma, unclassified B-cell lymphoma with features intermediate between DLBCL and classical Hodgkin's lymphoma (HL), primary effusion lymphoma, plasma lymphoma;
  • Toxicity not yet recovered from previous anti-tumor therapies;
  • Uncontrolled systemic infections or infections requiring intravenous antibiotics;
  • Have received steroid hormone, chemotherapy, targeted therapy, radiotherapy, antibody-based therapies, within a specified amount of time per protocol;
  • Unable to swallow tablets, or presence of significant functional gastrointestinal disorders that may affect the intake, transport or absorption of the study drug;
  • Have received autologous stem cell transplant,or allogeneic stem cell transplant within a certain amount of time as specified in protocol;
  • Presence of active graft-versus-host reaction;
  • Have undergone a major surgery within the last month;
  • Evidence of possible human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV) infection;
  • Have any cardiac impairment as defined per protocol;
  • Have prior history of malignancies other than diffuse large B-cell lymphoma (DLBCL).

Quoted from ClinicalTrials.gov, NCT03936153, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT03936153, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT03936153